Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals
EM, S., Nour El Din, D., Elawady, M., Ragab, S., El-Eraky, T. (2022). Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals. EKB Journal Management System, 39(2), 346-356. doi: 10.21608/bmfj.2022.114488.1525
Said EM; Dalia Nour El Din; Mona Ahmed Elawady; Shaimaa Yehia Ragab; Tamer E El-Eraky. "Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals". EKB Journal Management System, 39, 2, 2022, 346-356. doi: 10.21608/bmfj.2022.114488.1525
EM, S., Nour El Din, D., Elawady, M., Ragab, S., El-Eraky, T. (2022). 'Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals', EKB Journal Management System, 39(2), pp. 346-356. doi: 10.21608/bmfj.2022.114488.1525
EM, S., Nour El Din, D., Elawady, M., Ragab, S., El-Eraky, T. Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals. EKB Journal Management System, 2022; 39(2): 346-356. doi: 10.21608/bmfj.2022.114488.1525

Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals

Benha Medical Journal
Article 2, Volume 39, Issue 2, July and August 2022, Page 346-356  XML PDF (712.14 K)
Document Type: Original Article
DOI: 10.21608/bmfj.2022.114488.1525
View on SCiNiTO View on SCiNiTO
Authors
Said EM1; Dalia Nour El Din2; Mona Ahmed Elawady3; Shaimaa Yehia Ragab email 1; Tamer E El-Eraky1
1Hepatology,gastroentrology and infectious disease,Faculty of Medicine-Benha University
2Clinical and Chemical Pathology Benha Faculty of Medicine- Benha University
3Public Health and Community Medicine Department,Benha Faculty of Medicine- Benha University
Abstract
Background and Aims: In Egypt, compulsory vaccination against hepatitis B virus (HBV) infection started in 1992. Patients with chronic hepatitis C (CHC) should be vaccinated against HBV. The aim was to assess the response to HBV vaccine in CHC patients treated with direct acting antivirals (DDAs) in comparison to treatment-naive patients and healthy subjects. Method: This prospective study was carried out on 360 consecutive adult subjects subdivided into 3 groups. Group I included 150 CHC patients who vaccinated after getting sustained virologic response (SVR) following treatment with DAAs. Group II comprised 110 CHC treatment- naive patients while the control group comprised 100 healthy subjects. Three intramuscular 20 µg doses (at 0, 1 & 6 months) of HBV-vaccine (rDNA) were administered, HBs Ab titres were evaluated 6 – 8 weeks after the 3rd dose. Results: CHC patients (treated or treatment-naïve) had highly significant lower mean HBs Ab titre than controls. Twelve patients in group I (8%) had no response to HBV vaccine in comparison to 4.5% in group II and 1% controls. About 83.3%in group I compared to 85.5% in group II and 98% controls had a good response. In CHC treated patients, HBs Ab titre was negatively associated with FIB-4 score, fibrosis stage and ALT levels while positively associated with platelet count. The fibrosis stage was the most significant predictor of weak response. Conclusion: CHC Patients demonstrate a significantly weak response to HBV vaccine. Concomitant DAAs treatment does not influence response.
Keywords
Hepatitis B virus; Hepatitis C virus; Hepatitis B vaccine
Statistics
Article View: 169
PDF Download: 295